Articles

Women who have a tubal ligation are at an increased risk for cervical cancer due to less frequent Pap smears. Read More ›

New recommendations released by the American Cancer Society are based on evidence garnered from a review of the National Lung Screening Trial. Read More ›

When compared with a single measurement of prostate specific antigen, measurements taken over time improve accuracy when detecting aggressive prostate cancer. Read More ›

People who smoke more frequently have a greater chance of developing more aggressive and deadly bladder cancer. Read More ›

As cancer treatments emerge in pill form, patients meet many challenges when administering their own chemotherapy outside the supervised cancer clinic environment. Read More ›

This is the first article in a 4-part series on bendamustine. This article describes the history and characterization of bendamustine. Subsequent articles will discuss the efficacy and safety of bendamustine in registration studies and describe ongoing clinical investigations of bendamustine. Read More ›

Bendamustine has an interesting history that spans more than 50 years. Bendamustine was first synthesized in the early 1960s in the former East Germany. It was first used to treat multiple myeloma and was subsequently extended to patients with chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma. Read More ›

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and is a slowly progressing cancer of the blood and bone marrow. According to cancer statistics, an estimated 16,060 new CLL diagnoses will be made in the United States in 2012. Read More ›

Since the approval of bendamustine, healthcare practitioners have additional treatment options available to patients with specific hematologic malignancies. In the United States, bendamustine was approved for patients with chronic lymphocytic leukemia (CLL) or indolent B-cell non-Hodgkin lymphoma (NHL) who had progressed within 6 months of receiving rituximab-containing regimens. Read More ›

A small percentage of men in a recent study complained that their penis seemed shorter following prostate cancer treatment. Read More ›